Eric Flachbart

Vice President Regulatory Affairs at Byonyks

Eric Flachbart is an experienced executive in the medical devices and technology sectors, currently serving as the Vice President of Regulatory Affairs at Byonyks since January 2022. Flachbart has held various leadership roles, including President at Infusion Analytics LLC and IVmetrix LLC since November 2017 and President of Numia Medical Technology, LLC from 2005 to October 2016. Previously, Flachbart was the Chief Technology Officer at Byonyks Pvt LTD from September 2018 to January 2021 and held the position of Vice President at Harvard Clinical Technology from 1993 to 2005. Early in the career, Flachbart worked as a Reliability Engineer at Bard MedSystems and Textron Defense. Educational achievements include a degree from Merrimack College.

Links


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Byonyks

Byonyks has pioneered the world’s first affordable Bloodless Dialysis machine, transforming care for kidney failure patients. Globally, over eight million people with kidney disease lack dialysis access—a costly, invasive, and time-consuming treatment that filters blood when kidneys fail. Many of these individuals face life-threatening consequences due to the lack of proper care. Byonyks addresses this critical issue with its Bloodless Dialysis machine; a safe, effective, portable, and non-invasive solution that’s more affordable than existing options. Our technology empowers patients to perform dialysis at home, overnight, while they sleep, allowing them to maintain their daily work and family responsibilities. The needle-free approach also reduces the risk of chronic infections such as HIV and Hepatitis C. Headquartered in the USA and South Asia, Byonyks is a medical device startup founded by Harvard/MIT graduates and industry experts. Our core team’s expertise contributes to over half of the operational peritoneal dialysis machines worldwide. The groundbreaking Bloodless Dialysis machine has saved multiple lives in South Asia and is currently under FDA review—a pivotal step towards making accessible kidney care a global reality.


Employees

51-200

Links